Crohn’s Disease – Landscape & Forecast – Disease Landscape & Forecast
The Crohn’s disease (CD) therapy market is expected to see increasing use of biologics / targeted oral therapies and grow steadily over the next 10 years. The well-established TNF-α inhibitors (e.g., infliximab, adalimumab [AbbVie / Eisai’s Humira, biosimilars]), together with non-TNF biologics (i.e., Takeda’s Entyvio and Janssen’s Stelara), have transformed the treatment landscape for CD, especially for moderate to severe disease, despite these drugs’ efficacy limitations and safety risks. The impending entry of several new therapies offering more-convenient formulations and/or novel mechanisms of action (e.g., AbbVie’s Skyrizi and Rinvoq, Eli Lilly’s mirikizumab, Janssen’s Tremfya) will further improve treatment and intensify market competition. Together with these trends, the continuing generic erosion of conventional agents and the availability of biosimilar TNF-α inhibitors will constrain CD therapy sales.
QUESTIONS ANSWERED
- What are KOLs’ opinions of current targeted therapies (e.g., infliximab, adalimumab, Stelara, Entyvio)? How have biosimilars influenced treatment practices? What factors drive treatment decisions?
- What do KOLs think about emerging therapies (e.g., Skyrizi, Rinvoq, mirikizumab, Tremfya)? What impact will the stem cell therapy Alofisel (TiGenix / Takeda) and oral therapies have on the CD treatment algorithm?
- Which emerging agents are likely to be most successful in targeting TNF-refractory patients and experiencing uptake in the CD market?
- How will the market evolve over the next 10 years?
CONTENT HIGHLIGHTS
Geographies: United States, EU5, Japan.
Primary research: 25 country-specific interviews with thought-leading gastroenterologists supported by survey data collected for this and other Clarivate research.
Epidemiology: Diagnosed prevalence of CD by country, segmented by disease activity.
Forecast: 10-year, annualized, drug-level sales and patient share of key CD therapies through 2031, segmented by brands/generics.
Emerging therapies: Phase III/preregistered: ~7 drugs; coverage of select Phase I and Phase II products.
PRODUCT DESCRIPTION
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
SOLUTION ENHANCEMENT
Disease Landscape & Forecast features continual updates to provide timely insights and analyses as meaningful indication-specific news and events unfold.
Additionally, Disease Landscape & Forecast introduces a new Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.
Table of contents
- Crohn's Disease - Landscape & Forecast - Disease Landscape & Forecast
- Key findings
- Key updates
- April 2023
- Q4 2022
- December 2022
- November 2022
- Q3 2022
- September 2022
- August 2022
- July 2022
- Q2 2022
- June 2022
- May 2022
- April 2022
- Q1 2022
- March 2022
- February 2022
- January 2022
- Market outlook
- Key findings
- Market share of drug classes for Crohn's disease: 2021
- Market share of drug classes for Crohn's disease: 2031
- Patient share of major drug classes for Crohn's disease in the acute setting: 2021-2031
- Patient share of major drug classes for Crohn's disease in the maintenance setting: 2021-2031
- Crohn's disease SWOT analysis
- Market drivers and constraints
- What factors are driving the market for Crohn's disease?
- What factors are constraining the market for Crohn's disease?
- Drug-class-specific trends
- Total sales and patient share of TNF-alpha inhibitors: 2021-2031
- Total sales and patient share of IL-12/23 inhibitors: 2021-2031
- Total sales and patient share of CAM inhibitors: 2021-2031
- Total sales and patient share of IL-23 inhibitors: 2021-2031
- JAK inhibitors
- Total sales and patient share of JAK inhibitors: 2021-2031
- Sales of darvadstrocel (Alofisel) by country: 2021-2031
- Total sales and patient share of ozanimod: 2021-2031
- Key findings
- Forecast
- Market forecast assumptions
- Market forecast dashboard
- Etiology and pathophysiology
- Disease overview
- Key pathways and drug targets
- Key pathways in Crohn's disease
- Key drug targets and their biological function
- Disease overview
- Epidemiology
- Key findings
- Epidemiology populations
- Methods
- Sources used for diagnosed prevalent cases of Crohn's disease
- Diagnosed prevalent cases of Crohn's disease: 2021-2031 (thousands)
- Methods
- Sources used for diagnosed prevalent cases of Crohn's disease by disease activity
- Diagnosed prevalent cases of Crohn's disease by disease activity: 2021-2031 (thousands)
- Drug-treated prevalent cases of Crohn's disease: 2021-2031
- Key findings
- Current treatment
- Key findings
- Treatment goals
- Key endpoints used in clinical trials for Crohn's disease
- Key current therapies
- Overview
- Mechanism of action of key current drug classes used for Crohn's disease
- Current treatments used for Crohn's disease
- Market events impacting the use of key current therapies in Crohn's disease
- Expert insight: TNF-alpha inhibitors
- Advantages and disadvantages of infliximab
- Advantages and disadvantages of adalimumab
- Advantages and disadvantages of Cimzia
- Advantages and disadvantages of Tysabri
- Advantages and disadvantages of Entyvio
- Expert insight: Entyvio
- Ongoing clinical development of Entyvio
- Key ongoing clinical trials of Entyvio in the treatment of Crohn's disease
- Advantages and disadvantages of Stelara
- Expert insight: Stelara
- Ongoing clinical development of Stelara
- Key ongoing clinical trials of Stelara in the treatment of Crohn's disease
- Advantages and disadvantages of Skyrizi
- Expert insight: Skyrizi
- Ongoing clinical development of Skyrizi
- Key ongoing clinical trials of Skyrizi in the treatment of Crohn's disease
- Advantages and disadvantages of darvadstrocel (Alofisel)
- Expert insight: Darvadstrocel (Alofisel)
- Ongoing clinical development of darvadstrocel (Alofisel)
- Key ongoing clinical trials of darvadstrocel (Alofisel) in the treatment of Crohn's disease
- Advantages and disadvantages of 5-ASAs
- Expert insight: 5-ASAs
- Advantages and disadvantages of immunosuppressants
- Expert insight: Immunosuppressants
- Advantages and disadvantages of corticosteroids
- Expert insight: Corticosteroids
- Advantages and disadvantages of antibiotics
- Medical practice
- Overview
- Factors influencing drug selection in Crohn's disease
- Treatment decision tree for Crohn's disease: United States
- Treatment decision tree for Crohn's disease: Europe
- Treatment decision tree for Crohn's disease: Japan
- Key findings
- Unmet need overview
- Current and future attainment of unmet needs in Crohn's disease
- Top unmet needs in Crohn's disease: current and future attainment
- Expert insight: Unmet need in Crohn's disease
- Drug pipeline
- Pipeline
- Regulatory Milestones
- Indication Comparison
- Emerging therapies
- Key findings
- Key emerging therapies
- Key therapies in development for Crohn's disease
- Estimated launch dates of key emerging therapies for the treatment of Crohn's disease
- Guselkumab (Tremfya) profile
- Analysis of clinical development program for guselkumab (Tremfya)
- Expectations for launch and sales opportunity of guselkumab (Tremfya) in Crohn's disease
- Mirikizumab profile
- Analysis of the clinical development program for mirikizumab
- Expectations for launch and sales opportunity of mirikizumab in the treatment of Crohn's disease
- Brazikumab profile
- Analysis of clinical development program for brazikumab
- Expectations for launch and sales opportunity of brazikumab in Crohn's disease
- Expert insight: IL-23 inhibitors
- Upadacitinib (Rinvoq) profile
- Analysis of the clinical development program for upadacitinib (Rinvoq)
- Expert insight: upadacitinib (Rinvoq)
- Expectations for launch and sales opportunity of upadacitinib (Rinvoq) in Crohn's disease
- Ozanimod (Zeposia) profile
- Analysis of the clinical development program for ozanimod (Zeposia)
- Expert insight: ozanimod (Zeposia)
- Expectations for launch and sales opportunity of ozanimod (Zeposia) in Crohn's disease
- Etrasimod
- Etrasimod profile
- Analysis of the clinical development program for etrasimod
- Expert insight: Etrasimod
- RHB-104 profile
- Analysis of the clinical development program for RHB-104
- Expert insight: RHB-104
- Expectations for launch and sales opportunity of RHB-104 in Crohn's disease
- Early-phase pipeline analysis
- Select compounds in phase II development for Crohn's disease
- Key discontinuations and failures in Crohn's disease
- Key findings
- Access & reimbursement overview
- Region-specific reimbursement practices
- Key market access considerations in Crohn's disease: United States
- General reimbursement environment: United States
- Key market access considerations in Crohn's disease: EU5
- General reimbursement environment: EU5
- Key market access considerations in Crohn's disease: Japan
- General reimbursement environment: Japan
- Region-specific reimbursement practices
- Appendix
- Key abbreviations related to Crohn's disease
- Crohn's disease bibliography
- Key findings
Megha Bharadwaj, M.Tech., Healthcare Research & Data Analyst, Immune and Inflammation. Ms. Bharadwaj’s focus is the rheumatoid arthritis therapy market. To her role at Clarivate, she brings experience handling various types of commercial assessment projects. She has worked on a variety of opportunity assessment and market intelligence projects involving preparation of disease narratives, preparing forecast models, and market tracking for pharmaceutical and medical devices. She holds a master’s degree in biotechnology from Amity University in Noida, India.
Priya Dhadwal, B.D.S., M.P.H., is an associate epidemiologist at Clarivate. Previously, she worked with the National Aids Control Organisation in India as a research officer in HIV Sentinel Surveillance. She also worked in the healthcare financing division of the National Health Systems Resource Centre in the Ministry of Health and Family Welfare in New Delhi. She obtained her master’s degree in public health with a specialization in advanced epidemiology and biostatistics from the Post Graduate Institute of Medical Education and Research in Chandigarh, India, and her bachelor’s degree in dental surgery from HP Government Dental College in Shimla, India.